Revelation Biosciences Initiates 1-for-16 Reverse Split and Advances CKD Clinical Trial

Revelation Biosciences Advances Clinical Research Amid Structural Changes

Revelation Biosciences Inc. is poised for significant developments in its clinical research and corporate structure as it prepares for a 1-for-16 reverse stock split scheduled for January 28, 2025. This strategic move, approved during a Special Meeting of Stockholders on January 17, 2025, aims to enhance the company's share price to meet the Nasdaq Capital Market's minimum bid requirements. Following the split, shareholders will see their existing shares converted at a ratio of sixteen to one, preserving their proportional ownership, although fractional shares will be rounded down. This action is crucial for Revelation as it navigates the competitive landscape of biotechnology, where compliance with stock exchange regulations can significantly impact operational funding and investor confidence.

In addition to the reverse stock split, Revelation Biosciences is making strides in its clinical initiatives, particularly with the upcoming launch of its Prime Phase 1b clinical trial for Gemini, aimed at treating chronic kidney disease (CKD) patients. The company anticipates beginning dosing in mid-February 2025, with topline data expected to be released by mid-year. This timing is critical as it aligns with the company's efforts to bolster its market position and investor appeal through innovative therapies. The successful advancement of the Gemini study could not only enhance patient outcomes in CKD but also attract potential partnerships and funding opportunities.

Revelation's strategic initiatives reflect its commitment to both regulatory compliance and innovative research. As the company transitions through this corporate change, it underscores the importance of clinical advancements in maintaining shareholder value. Interested parties can stay informed about these developments through the company’s official website, where updates on the reverse stock split and clinical trials will be posted.

In tandem with its corporate restructuring, Revelation's management emphasizes that stockholders will not need to take any action to receive their new post-split shares, as adjustments will be made automatically by the company's transfer agent, Continental Stock Transfer & Trust Co. This seamless transition aims to minimize disruption for investors while focusing on the company's core mission of advancing medical research and development. For further inquiries regarding the reverse stock split, shareholders are encouraged to reach out to the transfer agent directly or visit Revelation's website for comprehensive information.